1. Home
  2. ADPT vs DGII Comparison

ADPT vs DGII Comparison

Compare ADPT & DGII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$14.08

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Digi International Inc.

DGII

Digi International Inc.

HOLD

Current Price

$56.43

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
DGII
Founded
2009
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer peripheral equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
2019
1995

Fundamental Metrics

Financial Performance
Metric
ADPT
DGII
Price
$14.08
$56.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
5
Target Price
$17.78
$48.80
AVG Volume (30 Days)
1.8M
241.9K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
63.89
77.05
EPS
N/A
0.31
Revenue
$276,976,000.00
$430,221,000.00
Revenue This Year
$3.98
$18.71
Revenue Next Year
$22.72
$7.22
P/E Ratio
N/A
$181.26
Revenue Growth
54.77
1.46
52 Week Low
$7.16
$26.69
52 Week High
$20.76
$56.88

Technical Indicators

Market Signals
Indicator
ADPT
DGII
Relative Strength Index (RSI) 49.32 69.29
Support Level $12.22 $47.00
Resistance Level $17.52 N/A
Average True Range (ATR) 0.84 1.76
MACD 0.06 0.23
Stochastic Oscillator 54.11 91.70

Price Performance

Historical Comparison
ADPT
DGII

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About DGII Digi International Inc.

Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.

Share on Social Networks: